The DOI matches its Crossref record.
Hepatogastroenterology
Abstract
BACKGROUND/AIMS: The current recommendation of ribavirin dose for the treatment of chronic hepatitis C is based on study results of Western patients, and might not be optimal for Korean patients because of different body frames. METHODOLOGY: A total of 163 treatment-naive genotype 1 chronic hepatitis C patients who received combination therapy with pegylated interferon a-2a and ribavirin were reviewed. RESULTS: Under current ribavirin dosing, only 49% of patients started therapy with ribavirin dose of 13-15mg/kg (targeted dose), while 45% and 6% of patients started therapy with ribavirin dose =16mg/kg and <13mg/kg, respectively. Patients who started therapy with higher ribavirin dose experienced more ribavirin dose modification during treatment (55%, 31% and 11% for ribavirin dose of =16mg/kg, 13-15mg/kg and <13mg/kg, respectively, p=0.002). The sustained virological response (SVR) rate was 66%, 63% and 56% for ribavirin dose of =16mg/kg, 13-15mg/kg and <13mg/kg, respectively (p=0.775). CONCLUSIONS: A certain proportion of Korean patients started therapy with a higher than targeted ribavirin dose, which resulted in more ribavirin dose modifications without definite additional benefit in achieving SVR. Therefore, the ribavirin dosing regimen might need to be reassessed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Radiofrequency Ablation of Hepatocellular Cancer in 110 Patients With Cirrhosis
Curley, S. A., Izzo, F., Ellis, L. M., Nicolas Vauthey, J., & Vallone, P. (2000) · Annals of Surgery · doi:10.1097/00000658-200009000-00010 · Cited by 731
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Pharmacological actions of melatonin in oxygen radical pathophysiology
Reiter, R., Tang, L., Garcia, J. J., & Muñoz-Hoyos, A. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00030-1 · Cited by 480
Adam, R., Chiche, L., Aloia, T., Elias, D., Salmon, R., Rivoire, M., Jaeck, D., Saric, J., Treut, Y. P. L., Belghiti, J., et al. (2006) · Transactions of the ... Meeting of the American Surgical Association · doi:10.1097/01.sla.0000239036.46827.5f · Cited by 411
Targher, G., Marra, F., & Marchesini, G. (2008) · Diabetologia · doi:10.1007/s00125-008-1135-4 · Cited by 378
Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control
Utzinger, J., & Keiser, J. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.2.263 · Cited by 329
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., et al. (2015) · Drugs · doi:10.1007/s40265-015-0434-6 · Cited by 152
Iwata, M., Kuzuya, M., Kitagawa, Y., & Iguchi, A. (2006) · Aging Clinical and Experimental Research · doi:10.1007/bf03324664 · Cited by 73
Jiang, L., Zhang, Y., Guo, L., Liu, C., Wang, P., & Ren, W. (2021) · BMC Cancer · doi:10.1186/s12885-021-09020-y · Cited by 59
Steffens, D., Nott, F., Koh, C., Jiang, W., Hirst, N., Cole, R., Karunaratne, S., West, M. A., Jack, S., & Solomon, M. J. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15593-2 · Cited by 53
Metadata
- Venue
- Hepatogastroenterology
- Publisher
- Update Medical Publishing
- Published
- 2011-09-27
- Volume
- 59
- Issue
- 113
- Pages
- 1-6
- ISSN
- 0172-6390 (ISSN-L)
- OpenAlex
- W2415257785
- Cited by
- 660
- References
- 0
- Type
- paratext
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.